{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-072930","form_type":"8-K","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2026-06-11T20:05:35+00:00","discovered_at":"2026-06-11T20:06:19.293431+00:00","generated_at":"2026-06-11T20:13:58.513400+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Tvardi stockholders elect directors, approve compensation, and ratify auditor","bullets":["Imran Alibhai, Cynthia Smith, and Sujal Shah elected as Class II directors with 3.51M, 3.39M, 3.51M votes for; 2.98M broker non-votes.","Non-binding advisory vote on executive compensation approved: 3.48M for, 0.16M against, 0.02M abstain.","Stockholders chose 1-year frequency for future advisory votes on executive compensation (3.45M votes for 1 year).","Ratification of Deloitte & Touche as independent auditor for FY2026 passed: 6.52M for, 0.06M against, 0.05M abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-072930","json":"https://secwatch.observer/filing/0001104659-26-072930.json","markdown":"https://secwatch.observer/filing/0001104659-26-072930.md","text":"https://secwatch.observer/filing/0001104659-26-072930.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465926072930/0001104659-26-072930-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465926072930/tm2617528d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T20:13:58.513400+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"072a6386ca1d31b653e458dcf41affec878715e0","claim":"Tvardi Therapeutics, Inc. shareholders approved Non-Binding, Advisory Vote on Executive Compensation at the 2026-06-09 meeting.","evidence_excerpt":"The stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers, by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 3,482,265 161,795 16,451 2,975,429","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1346830/000110465926072930/0001104659-26-072930-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-09"}],"fact_type":"shareholder_vote"},{"claim_id":"147b9c64eb4e27dedf2d2398c530665bb77dd482","claim":"Tvardi Therapeutics, Inc. shareholders approved Election of Directors at the 2026-06-09 meeting.","evidence_excerpt":"Imran Alibhai, Ph.D., Cynthia Smith and Sujal Shah were each elected to serve as a Class II director of the Company’s Board of Directors until the 2029 Annual Meeting of Stockholders","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1346830/000110465926072930/0001104659-26-072930-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-09"}],"fact_type":"shareholder_vote"},{"claim_id":"688f7c59aecd3ba377dc5793f6cc3d3ad99ef46e","claim":"Tvardi Therapeutics, Inc. shareholders approved Advisory Vote on the Frequency of Solicitation of Advisory Stockholder Approval of Executive Compensation at the 2026-06-09 meeting.","evidence_excerpt":"3,513,039 147,472 Cynthia Smith 3,392,877 267,634 Sujal Shah 3,507,652 152,859 Broker Non-Votes: 2,975,429 Proposal 2 – Non-Binding, Advisory Vote on Executive Compensation The stockholders approved,","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1346830/000110465926072930/0001104659-26-072930-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-09"}],"fact_type":"shareholder_vote"},{"claim_id":"f06e6b52c83890c585ca4853635fbe722b89749a","claim":"Tvardi Therapeutics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-06-09 meeting.","evidence_excerpt":"The stockholders ratified the selection by the Audit Committee of the Board of Directors of the Company of Deloitte & Touche LLP","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1346830/000110465926072930/0001104659-26-072930-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-09"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}